FDA Transparency Push Expands to Monitoring Safety of Vaccines and Other Regulated Products

Frank Vinluan / medcitynews - The FDA said consolidating safety reporting into a single platform, the Adverse Event Monitoring System (AEMS), will increase transparency and reduce costs. But like the legacy systems it replaces, AEMS reports are unverified so causation and frequency of…

AI Summary: The FDA is consolidating multiple safety reporting systems into a single public Adverse Event Monitoring System to centralize reports for drugs, biologics, vaccines, cosmetics and animal products. The move aims to improve transparency, reduce fragmented reporting, and streamline monitoring — a tidy solution if it works as promised.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

FDA weighs easing access to compounded peptides for patients / 6 wks

FDA links eight deaths to Amgen’s Tavneos; scrutiny intensifies / 1 month

FDA launches individualized therapy framework for ultra-rare diseases / 3 months

FDA makes one pivotal trial the default for drug approvals / 3 months

FDA to review Moderna’s experimental flu vaccine after reversal / 3 months

FDA refuses to review Moderna mRNA flu vaccine application / 3 months

FDA rejects Atara cell therapy for Epstein–Barr virus complications / 4 months